Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer

Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Differentiation / immunology
  • Cell Growth Processes / immunology
  • Humans
  • Immunosuppressive Agents / immunology*
  • Immunotherapy / methods
  • Myeloid Cells / cytology
  • Myeloid Cells / immunology*
  • Myeloid Cells / pathology
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy*

Substances

  • Immunosuppressive Agents